This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00387/identifier/chebi/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/mesh/concept/
n7http://linked.opendata.cz/resource/drugbank/company/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00387/identifier/pharmgkb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00387/identifier/wikipedia/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00387/identifier/kegg-compound/
n20http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB00387/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n4http://linked.opendata.cz/resource/drugbank/drug/DB00387/identifier/pubchem-substance/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00387/identifier/drugbank/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n25http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n23http://www.drugs.com/cdi/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00387/identifier/national-drug-code-directory/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00387/identifier/chemspider/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00387
rdf:type
n5:Drug
n5:description
A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. [PubChem]
n5:generalReferences
# Theodoridis GC, Stark L: Central role of solar information flow in pregenetic evolution. J Theor Biol. 1971 Jun;31(3):377-88. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/5556140
n5:group
approved
n5:indication
For the treatment of all forms of Parkinson's Disease, as well as control of extrapyramidal reactions induced by antipsychotic agents.
n5:manufacturer
n7:271B3F3D-363D-11E5-9242-09173F13E4C5
owl:sameAs
n13:DB00387 n20:DB00387
dcterms:title
Procyclidine
adms:identifier
n4:46505553 n14:4919 n15:C07378 n16:61570-059-01 n17:DB00387 n18:8448 n19:4750 n21:Procyclidine n24:PA164784001
n5:mechanismOfAction
The mechanism of action is unknown. It is thought that Procyclidine acts by blocking central cholinergic receptors, and thus balancing cholinergic and dopaminergic activity in the basal ganglia. Many of its effects are due to its pharmacologic similarities with atropine. Procyclidine exerts an antispasmodic effect on smooth muscle, and may produce mydriasis and reduction in salivation.
n5:synonym
1-Cyclohexyl-1-phenyl-3-pyrrolidino-1-propanol Prociclidina Procyclidinum 1-cyclohexyl-1-phenyl-3-pyrrolidin-1-yl-propan-1-ol hydrochloride Procyclidin Procyclidine Tricyclamol
n5:toxicity
LD<sub>50</sub>=60 mg/kg (IV in mice)
n8:hasAHFSCode
n9:12-08-04
n5:proteinBinding
Approximately 100% bound to albumin.
n5:salt
n26:hasConcept
n27:M0017638
foaf:page
n23:procyclidine.html
n5:IUPAC-Name
n6:271B3F45-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B3F4B-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B3F4A-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B3F47-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B3F48-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B3F49-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B3F5B-363D-11E5-9242-09173F13E4C5 n6:271B3F43-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B3F5D-363D-11E5-9242-09173F13E4C5 n6:271B3F44-363D-11E5-9242-09173F13E4C5 n6:271B3F41-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B3F42-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n11:N04AA04
n5:H-Bond-Acceptor-Count
n6:271B3F51-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B3F52-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B3F4C-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B3F4D-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B3F4F-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B3F4E-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B3F50-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
77-37-2
n5:category
n5:containedIn
n25:271B3F3F-363D-11E5-9242-09173F13E4C5 n25:271B3F40-363D-11E5-9242-09173F13E4C5 n25:271B3F3E-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B3F57-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B3F59-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B3F5A-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B3F5C-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B3F56-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B3F55-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B3F58-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B3F46-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B3F53-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B3F54-363D-11E5-9242-09173F13E4C5